BridgeBio grabs a second priority review for the portfolio — giving Perceptive startup cause to celebrate

Just weeks after getting its first NDA in — and grabbing priority review from the FDA in the process — BridgeBio says it’s lined up a second potential speedy approval for the portfolio.